What's new

Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 7, Status: Authorised

Apr 9, 2025 - 13:27
 0
Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Vyloy, Zolbetuximab, D...

Next Article

Renewable Energy Still Alive And Kicking In The US

Related Posts

Product-specific bioequivalence guidance

Product-specific bioequivalence guidance

Feb 10, 2025  0

Orphan designation: Adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene Treatment of Huntington’s disease, 01/04/2019 Withdrawn

Orphan designation: Adeno-associated viral vector serot...

Mar 12, 2025  0

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Date of refusal: 25/04/2013, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 24, 2025  0